Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy(TM)

Stock Information for Vivos Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vivos Inc

Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
Vivos Inc Updates Human Therapy Progress in India
Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL(TM) Trademark Approvals
Vivos Inc Summarizes Progress in its Animal Therapy Division
Vivos Inc Summarzes Preogress in its Animal Therapy Division
Vivos Inc. Issues Shareholder Update Letter
Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel®

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.